{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1364233270301764096.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1158/1078-0432.ccr-07-4622"}},{"identifier":{"@type":"URI","@value":"https://aacrjournals.org/clincancerres/article-pdf/14/11/3268/1977644/3268.pdf"}}],"dc:title":[{"@value":"Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title>\n               <jats:p>Purpose: The purpose of this study was to characterize the activity of the Bcl-2 protein family inhibitor ABT-263 in a panel of small cell lung cancer (SCLC) xenograft models.</jats:p>\n               <jats:p>Experimental Design: A panel of 11 SCLC xenograft models was established to evaluate the efficacy of ABT-263. Single agent activity was examined on a continuous dosing schedule in each of these models. The H146 model was used to further evaluate dose and schedule, comparison to standard cytotoxic agents, and induction of apoptosis.</jats:p>\n               <jats:p>Results: ABT-263 exhibited a range of antitumor activity, leading to complete tumor regression in several models. Significant regressions of tumors as large as 1 cc were also observed. The efficacy of ABT-263 was also quite durable; in several cases, minimal tumor regrowth was noted several weeks after the cessation of treatment. Antitumor effects were equal or superior to that of several clinically approved cytotoxic agents. Regression of large established tumors was observed through several cycles of therapy and efficacy was retained in a Pgp-1 overexpressing line. Significant efficacy was observed on several dose and therapeutic schedules and was associated with significant induction of apoptosis.</jats:p>\n               <jats:p>Conclusions: ABT-263 is a potent, orally bioavailable inhibitor of Bcl-2 family proteins that has recently entered clinical trials. The efficacy data reported here suggest that SCLC is a promising area of clinical investigation with this agent.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1384233270301764102","@type":"Researcher","foaf:name":[{"@value":"Alex R. Shoemaker"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764108","@type":"Researcher","foaf:name":[{"@value":"Michael J. Mitten"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764225","@type":"Researcher","foaf:name":[{"@value":"Jessica Adickes"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764226","@type":"Researcher","foaf:name":[{"@value":"Scott Ackler"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764098","@type":"Researcher","foaf:name":[{"@value":"Marion Refici"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764106","@type":"Researcher","foaf:name":[{"@value":"Debra Ferguson"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764105","@type":"Researcher","foaf:name":[{"@value":"Anatol Oleksijew"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764103","@type":"Researcher","foaf:name":[{"@value":"Jacqueline M. O'Connor"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764228","@type":"Researcher","foaf:name":[{"@value":"Baole Wang"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764224","@type":"Researcher","foaf:name":[{"@value":"David J. Frost"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764099","@type":"Researcher","foaf:name":[{"@value":"Joy Bauch"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764107","@type":"Researcher","foaf:name":[{"@value":"Kennan Marsh"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764104","@type":"Researcher","foaf:name":[{"@value":"Steven K. Tahir"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764096","@type":"Researcher","foaf:name":[{"@value":"Xiufen Yang"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764227","@type":"Researcher","foaf:name":[{"@value":"Christin Tse"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764100","@type":"Researcher","foaf:name":[{"@value":"Stephen W. Fesik"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764101","@type":"Researcher","foaf:name":[{"@value":"Saul H. Rosenberg"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270301764097","@type":"Researcher","foaf:name":[{"@value":"Steven W. Elmore"}],"jpcoar:affiliationName":[{"@value":"Authors' Affiliation: Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"10780432"},{"@type":"EISSN","@value":"15573265"}],"prism:publicationName":[{"@value":"Clinical Cancer Research"}],"dc:publisher":[{"@value":"American Association for Cancer Research (AACR)"}],"prism:publicationDate":"2008-06-01","prism:volume":"14","prism:number":"11","prism:startingPage":"3268","prism:endingPage":"3277"},"reviewed":"false","url":[{"@id":"https://aacrjournals.org/clincancerres/article-pdf/14/11/3268/1977644/3268.pdf"}],"createdAt":"2008-06-02","modifiedAt":"2022-06-11","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050287685056633600","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002216803150592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002216804264960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002219915459968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142919129856","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283691764163328","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567183352175872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846642063414400","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567585206400","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Senescence‐associated secretory phenotype promotes chronic ocular graft‐vs‐host disease in mice and humans"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593672141056","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Radioimmunotherapy with an <sup>211</sup>At‐labeled anti–tissue factor antibody protected by sodium ascorbate"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814750932096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Cellular senescence promotes meibomian gland dysfunction in a chronic graft-versus-host disease mouse model"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1158/1078-0432.ccr-07-4622"},{"@type":"CROSSREF","@value":"10.1038/ncomms16078_references_DOI_H8KLdOnTTsHX03weERCIoSjSSI6"},{"@type":"CROSSREF","@value":"10.1038/ncomms7377_references_DOI_H8KLdOnTTsHX03weERCIoSjSSI6"},{"@type":"CROSSREF","@value":"10.1111/cas.14569_references_DOI_H8KLdOnTTsHX03weERCIoSjSSI6"},{"@type":"CROSSREF","@value":"10.1038/cddis.2014.561_references_DOI_H8KLdOnTTsHX03weERCIoSjSSI6"},{"@type":"CROSSREF","@value":"10.18632/oncotarget.5881_references_DOI_H8KLdOnTTsHX03weERCIoSjSSI6"},{"@type":"CROSSREF","@value":"10.1038/cddis.2014.6_references_DOI_H8KLdOnTTsHX03weERCIoSjSSI6"},{"@type":"CROSSREF","@value":"10.1038/s41419-020-2379-2_references_DOI_H8KLdOnTTsHX03weERCIoSjSSI6"},{"@type":"CROSSREF","@value":"10.1073/pnas.1411848112_references_DOI_H8KLdOnTTsHX03weERCIoSjSSI6"},{"@type":"CROSSREF","@value":"10.1096/fj.201900218r_references_DOI_H8KLdOnTTsHX03weERCIoSjSSI6"},{"@type":"CROSSREF","@value":"10.1111/cas.14857_references_DOI_H8KLdOnTTsHX03weERCIoSjSSI6"},{"@type":"CROSSREF","@value":"10.1016/j.jtos.2024.03.006_references_DOI_H8KLdOnTTsHX03weERCIoSjSSI6"}]}